Agios Pharmaceuticals, Inc. (AGIO) Stock Price & How to Invest
Last updated November 2026
Short answer
AGIO is Agios Pharmaceuticals, a US commercial-stage biotech built around mitapivat (branded PYRUKYND and AQVESME), a first-in-class pyruvate kinase activator for rare blood disorders. It is a clinical-catalyst story: fast-growing but still small product revenue, deep losses, a cash pile of about $907 million funding the launch, and an FDA decision on sickle cell disease that slipped from November 1, 2026 to February 1, 2027.
AGIO stock price
As of 2026-11-20, Agios Pharmaceuticals, Inc. (AGIO) last closed at $27.60, up 9.4% over the past year. Over the past 52 weeks it has traded between $24.43 and $44.01.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Agios Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
AGIO key stats
At $27.60 on November 20, 2026, Agios Pharmaceuticals, Inc. (AGIO) has a market cap of $1.6B.
- Market cap
- $1.6B
- Price to book
- 1.7
- Beta
- 0.62
Market cap, P/E and yield are measured at the $27.60 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Agios Pharmaceuticals, Inc. (AGIO)?
The last two weeks for Agios Pharmaceuticals, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- AGIO closed at $27.60 on November 20, 2026, down 12.6% over the past five trading days (from $31.59).
Agios Pharmaceuticals, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Agios Pharmaceuticals, Inc. (AGIO) latest quarter
Agios Pharmaceuticals reported revenue of $55.4 million for Q3 2026, up 330% from a year earlier (Agios Pharmaceuticals, Nov 5, 2026).
Source: Agios Pharmaceuticals Q3 2026 results, Nov 5, 2026. Full earnings breakdown
What does Agios Pharmaceuticals, Inc. (AGIO) do?
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia (US launch January 2026; PYRUKYND was also approved for thalassemia in the EU in late May 2026). The company is pursuing accelerated approval of mitapivat in sickle cell disease. The FDA granted Priority Review to that application in 2026 with a decision expected by November 1, 2026, but in late October it extended the goal date by three months to February 1, 2027, after asking for more information on whether a REMS (a formal risk-management program) is needed and classifying Agios' response as a major amendment. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).
The investment picture is a classic emerging-biotech profile. Product revenue is real but small: roughly $54 million in full-year 2025, then about $20.7 million in Q1 2026, $44.7 million in Q2 and $55.4 million in Q3 2026, up from $12.9 million a year earlier as the thalassemia launch took hold. Research and commercial spending keep the company deeply unprofitable, with a trailing-twelve-month net loss of about $373 million, though the quarterly loss narrowed to $1.09 per share in Q3. Cash, equivalents and marketable securities were about $907 million at September 30, 2026 (down from $1.16 billion at the end of 2025), with debt near $27 million, against free cash outflow of roughly $264 million over the trailing year. Management is targeting non-GAAP profitability in 2028 and is cutting more than 100 R&D roles by the end of 2026. The upside case rests on mitapivat expanding into far larger indications like sickle cell and thalassemia; the downside case is that trials or regulators disappoint and the franchise stays niche while cash burns. Tebapivat, the next-generation PK activator, is gone: Agios stopped it in lower-risk MDS in May 2026 after a missed efficacy threshold and in sickle cell in July 2026 because the data were not differentiated enough from existing PK activators.
The share price has tracked that mix. AGIO fell about 18% on October 30, 2026 when the FDA extension was disclosed, and closed at $28.35 on November 20, 2026: up about 4% year to date and about 15% over twelve months, but down about 23% over the past month and 16% over three months. The market value is about $1.7 billion. Third-quarter results on November 5 beat on both lines, with a loss of $1.09 per share against about $1.23 expected and revenue of $55.4 million against roughly $52 million. Agios plans to present 14 abstracts at the ASH meeting on December 12-15, 2026, including longer-term RISE UP sickle cell data and early AG-236 data in polycythemia vera.
What's driving Agios Pharmaceuticals, Inc. (AGIO)?
1. Mitapivat franchise expansion
Agios is trying to grow mitapivat from a small PK-deficiency drug into a multi-disease franchise. AQVESME launched in US thalassemia in January 2026, with 619 cumulative prescriptions with completed start forms by September 30 and about 75% of patients still on therapy after six months. US net product revenue for PYRUKYND and AQVESME together reached $48.7 million in the third quarter, plus $6.6 million outside the US. The company is pursuing accelerated FDA approval in sickle cell disease, a much larger market. Each new indication meaningfully widens the potential patient base for a single molecule, and analysts model revenue of about $185 million in 2026 and $349 million in 2027.
2. Sickle cell decision, now February 2027
The FDA granted Priority Review to Agios' supplemental application for mitapivat in sickle cell disease, but the goal date moved from November 1, 2026 to February 1, 2027 after the agency requested information on whether a REMS is needed. Agios says it is launch-ready and is in labeling discussions that include possible REMS elements. A sickle cell approval would be the single largest addressable-market event for the company. A rejection, a further delay or a restrictive REMS would hit hard, because the pipeline no longer has tebapivat behind it, and Novo Nordisk's competing PK activator etavopivat is advancing toward its own regulatory submission. Phase 3 RISE UP data at ASH in December show hemoglobin gains lasting up to 115 weeks.
3. Strong balance sheet plus Servier royalty
Agios reported about $907 million of cash, equivalents and marketable securities at September 30, 2026 with minimal debt, which management says is enough to fund the AQVESME launch, a potential sickle cell launch and the pipeline. Free cash flow was about -$264 million over the trailing year, and the R&D headcount cut (over 35% versus 2025) should lower spending in 2027 on the way to a 2028 non-GAAP profitability target. Agios also collects a royalty on US sales of Servier's Voranigo, a non-dilutive stream tied to a growing brain-cancer drug.
4. A narrower pipeline after tebapivat
Agios had framed 2026 as a year of multiple inflection points, with tebapivat, a next-generation PK activator, as the main follow-on. That program ended in 2026: development in lower-risk MDS stopped in May after a Phase 2b miss, and the sickle cell program stopped in July when Phase 2 data improved hemoglobin and hemolysis but were not differentiated enough from existing PK activators. The company's value is now concentrated in mitapivat and the Voranigo royalty. AG-236, an early-stage program in polycythemia vera, has Phase 1 data in healthy volunteers that support dosing every six months, to be presented at ASH 2026, and any further pipeline additions would be watched closely.
What are the risks to Agios Pharmaceuticals, Inc. (AGIO)?
Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. The business now depends almost entirely on a single molecule, so a negative trial or regulatory setback is materially damaging; tebapivat's discontinuation in both MDS and sickle cell in 2026 removed the main backup. The sickle cell decision, pushed to February 1, 2027, is binary, could come with a REMS that limits uptake, and accelerated approval would require a confirmatory trial that could still fail. Sickle cell and thalassemia are competitive markets with gene therapies, Novo Nordisk's etavopivat and other novel agents. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is solid today, sustained losses without pipeline success would eventually pressure it.
What is the Agios Pharmaceuticals, Inc. (AGIO) forecast?
9 analysts publish price targets on AGIO, averaging $46.11 as of November 2026, or +67.1% against the $27.60 share price on November 20, 2026. The published targets run from $32.00 to $74.00, a wide spread, and the ratings split 7 buy, 3 hold, 0 sell. Over the last six months there have been 8 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full AGIO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is AGIO a buy or a sell?
We give no verdict on Agios Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Mitapivat franchise expansion. Agios is trying to grow mitapivat from a small PK-deficiency drug into a multi-disease franchise. The most optimistic published target, $74.00, assumes this works close to its best case.
The case against. Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. The most pessimistic target, $32.00, is roughly what AGIO is worth if this bites instead.
Read the full bull and bear case on AGIO, including what would have to change to break either one. Walnut is not an investment adviser.
Has Agios Pharmaceuticals, Inc. (AGIO) split its stock?
No. Agios Pharmaceuticals, Inc. (AGIO) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Agios Pharmaceuticals, Inc. (AGIO) valued?
Market cap, P/E and dividend yield at today's price are in the AGIO key stats above. The business figures below come from Agios Pharmaceuticals, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$141M
- Q3 2026 revenue: ~$55.4M (vs ~$12.9M a year earlier), ahead of ~$52M expected
- Q3 2026 EPS: ~-$1.09 vs ~-$1.23 expected
- Net loss (TTM): ~-$373M; free cash flow ~-$264M
- Cash & marketable securities: ~$907M (Sept 30, 2026); debt ~$27M
As of November 2026: Agios trades at about 12 times trailing revenue, down from about 19 times in October as sales grew and the stock fell on the FDA extension, and the valuation still rests on the sickle cell opportunity rather than current earnings. Analysts expect revenue of about $185 million in 2026 and $349 million in 2027, with losses narrowing to about -$3.00 per share in 2027. The nine covering analysts carry a buy rating and a mean target of about $46 (BofA trimmed its target to $48 from $50 after the quarter), well above the price.
Who competes with Agios Pharmaceuticals, Inc. (AGIO)?
Sickle cell disease therapies
Companies with approved or developing sickle cell treatments, including gene therapies like Vertex and CRISPR Therapeutics' Casgevy, plus Pfizer (which acquired Oxbryta) and Novartis (Adakveo). These represent alternative treatment approaches in a market Agios is trying to enter with mitapivat.
PK activators and rare-hematology developers
Other developers of pyruvate kinase activators and rare blood-disorder drugs, notably Novo Nordisk (which is advancing etavopivat, a competing PK activator). This is the most direct competitive overlap with Agios' core mechanism.
Thalassemia and transfusion-dependent anemia treatments
Therapies for thalassemia and related anemias, including Bristol Myers Squibb's Reblozyl (luspatercept) and bluebird bio's gene therapy Zynteglo, which compete for the same patient populations AQVESME targets.
What stocks are similar to Agios Pharmaceuticals, Inc. (AGIO)?
Other names that sit close to AGIO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Agios Pharmaceuticals, Inc. (AGIO)
There are three common ways to get AGIO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AGIO sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where AGIO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Agios Pharmaceuticals, Inc. (AGIO)
AGIO is a rare-disease biotech whose value hinges on turning one approved PK activator into a multi-indication franchise. With tebapivat discontinued in 2026, the company is now essentially a single-molecule story, and the FDA's sickle cell decision, now due by February 1, 2027 after a three-month extension over a possible REMS, is the defining near-term event. The shares closed at $28.35 on November 20, 2026, up about 4% this year but down about 23% over the past month after the delay; the balance sheet buys time, but ongoing losses and binary regulatory outcomes define the risk.
More on Agios Pharmaceuticals, Inc. (AGIO)
Whether AGIO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AGIO a buy or a sell?, and where the stock could go from here in the AGIO stock forecast.
For income investors, whether AGIO pays a dividend and how the payout looks is covered in does AGIO pay a dividend? And to weigh AGIO against a peer, read the full side-by-side comparisons: AGIO vs VERX and AGIO vs CRSP.
Wondering how AGIO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Agios Pharmaceuticals, Inc.
Ask Walnut's AI anything about AGIO and see how it fits what you own.
FAQ
What does Agios Pharmaceuticals do?
+
Agios develops medicines for rare hematologic (blood) diseases. Its main product is mitapivat, a pyruvate kinase activator sold as PYRUKYND for PK deficiency and AQVESME for thalassemia, and it is pursuing approval in sickle cell disease, with an FDA decision due by February 1, 2027.
Is AGIO profitable?
+
No. Agios reported GAAP losses of about $1.69 per share in both Q1 and Q2 2026 and $1.09 in Q3, and a net loss of about $373 million over the trailing year. Research and commercial spending far exceed its product revenue (about $55.4 million in Q3 2026), so the company remains deeply unprofitable. Management is targeting non-GAAP profitability in 2028.
How much revenue does Agios generate?
+
Agios reported about $54 million in full-year 2025 revenue, roughly $20.7 million in Q1 2026, about $44.7 million in Q2 and about $55.4 million in Q3 2026, up from $12.9 million a year earlier. Trailing-twelve-month revenue was about $141 million as of September 2026, and analysts expect about $185 million for full-year 2026.
What is mitapivat (PYRUKYND and AQVESME)?
+
Mitapivat is an oral pyruvate kinase activator. It is approved in the US as PYRUKYND for pyruvate kinase deficiency and as AQVESME for thalassemia, and PYRUKYND was approved for thalassemia in the EU in May 2026. Agios is seeking accelerated approval for its use in sickle cell disease.
What happened with tebapivat?
+
In May 2026 Agios discontinued tebapivat development in lower-risk myelodysplastic syndromes after a Phase 2b trial failed to meet its efficacy threshold for durable transfusion independence. In July 2026 it also stopped the sickle cell program: Phase 2 data showed improvements in hemoglobin and hemolysis but not enough differentiation from existing PK activators. Tebapivat is now discontinued across all indications.
How much cash does Agios have?
+
Agios reported about $907 million of cash, cash equivalents and marketable securities as of September 30, 2026, down from $1.16 billion at the end of 2025, with debt near $27 million. Free cash flow was about -$264 million over the trailing year. Management says the balance funds the AQVESME launch, a potential sickle cell launch and the pipeline without an immediate need to raise money.
What is the Priority Review news about?
+
The FDA granted Priority Review to Agios' supplemental application for mitapivat in sickle cell disease, with a decision originally expected by November 1, 2026. In late October the FDA extended that date by three months to February 1, 2027, after asking whether a REMS is needed and treating Agios' response as a major amendment. Sickle cell is a much larger market than PK deficiency or thalassemia, so the outcome is the biggest single event for the stock.
What are the main risks with AGIO?
+
Key risks include heavy ongoing losses, dependence on a single molecule, the delayed sickle cell decision and a possible REMS, competitive markets including gene therapies, and binary trial and regulatory outcomes. Walnut is not an investment adviser, and this page is descriptive information, not a recommendation.
How did Agios do in its latest quarter?
+
In the third quarter of 2026, reported November 5, Agios posted total revenue of about $55.4 million, up from $12.9 million a year earlier and ahead of the roughly $52 million consensus, driven by the AQVESME thalassemia launch. The loss of $1.09 per share was narrower than the ~$1.23 expected and the $1.78 loss a year earlier. Cash and marketable securities ended the quarter at about $907 million.
How has AGIO stock performed in 2026?
+
As of the November 20, 2026 close of $28.35, AGIO was up about 4% year to date and about 15% over the past year, with a 52-week range of roughly $23 to $44. The shares fell about 18% on October 30 after the FDA pushed the sickle cell decision to February 2027 and were down about 23% over the past month. Past performance does not predict future results, and Walnut is not an investment adviser.
Why did AGIO stock fall in late October 2026?
+
On October 30, 2026 the stock dropped about 18% after Agios disclosed that the FDA had extended its review of mitapivat in sickle cell disease by three months, to February 1, 2027. The FDA wanted more information on whether a REMS is required, and Agios' response counted as a major amendment. The company says it remains launch-ready.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Agios Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.